Radius Health, Inc. (Nasdaq: RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial InVertebral Endpoints) trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Radius Health (RDUS) Trades to Session LowsOctober 12, 2015 2:41 PM Radius Health (RDUS), Dyax Corp (DYAX) Highlighted as Speculative Takeover PlaysOctober 12, 2015 12:06 PM Canaccord Genuity Reiterates Buy on Radius Health (RDUS) Following ASBMR Presentation October 12, 2015 9:10 AM Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual MeetingOctober 10, 2015 7:15 PM